Skip Navigation

Corrigendum for Souquet et al., Ann Oncol 13 (12) 1853-1861.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:347, 2003
© 2003 European Society for Medical Oncology

GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine–cisplatin with vinorelbine–ifosfamide–cisplatin in metastatic non-small-cell lung cancer patients Ann Oncol 2002; 13: 1853–1861

The authors wish to apologise for the omission from the Acknowledgements of the following GLOB-1 investigators:

O. Fernandez, Centro Oncologico, Avellaneda, Argentina; C. Lewis, Prince of Wales Hospital, Sydney, Australia; P. De Souza, St George Hospital, Sydney, Australia; L. Bosque, Hôpital de la Citadelle, Liège, Belgium; J. Rodrigues Pereira, Instituto Arnaldo Vieisa de Carvalho, Sao Paulo, Brazil; V. Kolec, University Hospital Olomouc, Czech Republic; M. Marel, University Hospital Motol, Praha, Czech Republic; P. Astoul, Hôpital de la Conception, Marseille, Fance; V. Jounieaux, Hôpital Sud, Amiens, Fance; R. Riou, Centre Hospitalier de Valence, Fance; P.J. Souquet, Centre Hospitalier, Lyon-Sud, France; V. Tack, Centre Hospitalier de Calais, Fance; K.M. Deppermann, Fachkrankenhaus für Lungenheilkunde, Berlin, Germany; U. Gatzemeier, Krankenhaus, Großhansdorf, Germany; G. Koschel, Allgemeines Krankenhaus Harburg, Germany; E.D. Kreuser, Krankenhaus der Barmherzigen Brüder, München, Germany; G. Schlimok, Universitätsklinik, Augsburg, Germany; J. Von Pawel, Zentral Krankenhaus der LVA, Gauting, Germany; O.P. Isokangas, Helsinki University Central Hospital, Finland; K. Mattson, Helsinki University Central Hospital, Finland; L. Torrecillas, Centro Medico Nacional "20 de Noviembre", Mexico; V. Lira Puerto, Centro Medico Nacional Siglo XXI, Mexico; N. Barroso, Hospital Dr A. Leaño, Zapopan, Mexico; R. Von Klaveren, Klinick Longarts, Rotterdam, The Netherlands; D. Gallardo, Intituto Nacional de Cancerologia, Tlalpan, Mexico; B. Utraka, Centrum Onkologii, Gliwice, Poland; P. Barnardt, Tygerberg Hospital, Capetown, South Africa; E.H. Tan, National Cancer Centre, Singapore; I. Sevilla Garcia, Hospital Virgen de la Victoria, Malaga, Spain; J.A. Moreno Nogueira, Hospital Virgen del Rocío, Sevilla, Spain; D. Betticher, Institute of Medical Oncology, Inselspital, Bern, Switzerland; R. Stahel, Universitatsspital, Zurich, Switzerland; M. Wernli, Kantonsspital, Aarau, Switzerland; J.F. Shih, Veterans General Hospital, Taïwan; P. Clark, Clatterbridge Centre of Oncology, Merseyside, UK; P. Harper, Guy’s Hospital, London, UK; A. Price, Western General Hospital, Edinburgh, UK.

DOI: 10.1093/annonc/mdg083


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?